The LungFit PH device was approved ini 2022 by the U.S. Food and Drug Administration and the European Union to treat PPHN.
An imaging technique called 18F-FAPI PET may be able to detect early signs of changes in blood vessel tissues in PAH, a new ...
A possibly more precise risk model showed Adempas helped PAH patients at intermediate risk of death arrive at more favorable ...
The dosing regimen for Winrevair is optimal for balancing safety and effectiveness in adults with PAH, according to clinical ...
Body weight-adjusted Uptravi (selexipag) dosing for children and adolescents with pulmonary arterial hypertension (PAH) resulted in exposure to the treatment’s active ingredient comparable to that in ...
The U.S. Food and Drug Administration (FDA) has provided Tiakis Biotech with advice for a planned Phase 2 clinical trial testing tiprelestat for pulmonary arterial hypertension (PAH). The ATHENA trial ...
It’s a beautiful day in the country for what appears to be the beginning of autumn. There are acres of trees, mostly green except for a few that have changed to gold. They’re casting a shadow over a ...
The U.S. Food and Drug Administration (FDA) has granted orphan drug designation to ALG-801, Alivegen ’s experimental treatment for pulmonary arterial hypertension (PAH).
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback